Nuvation Bio, Inc. (NUVB)
6.96
+0.20
(+2.96%)
USD |
NYSE |
Aug 25, 14:46
Nuvation Bio Enterprise Value : 2.120B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.120B |
| August 21, 2026 | 2.180B |
| August 20, 2026 | 2.145B |
| August 19, 2026 | 2.295B |
| August 18, 2026 | 2.190B |
| August 17, 2026 | 2.022B |
| August 14, 2026 | 1.931B |
| August 13, 2026 | 1.889B |
| August 12, 2026 | 2.001B |
| August 11, 2026 | 1.984B |
| August 10, 2026 | 2.064B |
| August 07, 2026 | 2.064B |
| August 06, 2026 | 1.893B |
| August 05, 2026 | 1.984B |
| August 04, 2026 | 2.008B |
| August 03, 2026 | 1.910B |
| July 31, 2026 | 1.970B |
| July 30, 2026 | 2.099B |
| July 29, 2026 | 2.061B |
| July 28, 2026 | 2.096B |
| July 27, 2026 | 2.085B |
| July 24, 2026 | 2.001B |
| July 23, 2026 | 2.026B |
| July 22, 2026 | 2.047B |
| July 21, 2026 | 2.005B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.945B |
| July 17, 2026 | 1.784B |
| July 16, 2026 | 1.728B |
| July 15, 2026 | 1.819B |
| July 14, 2026 | 1.819B |
| July 13, 2026 | 1.774B |
| July 10, 2026 | 1.788B |
| July 09, 2026 | 1.893B |
| July 08, 2026 | 1.809B |
| July 07, 2026 | 1.739B |
| July 06, 2026 | 1.714B |
| July 02, 2026 | 1.749B |
| July 01, 2026 | 1.651B |
| June 30, 2026 | 1.742B |
| June 29, 2026 | 1.627B |
| June 26, 2026 | 1.641B |
| June 25, 2026 | 1.696B |
| June 24, 2026 | 1.922B |
| June 23, 2026 | 1.776B |
| June 22, 2026 | 1.679B |
| June 18, 2026 | 1.610B |
| June 17, 2026 | 1.530B |
| June 16, 2026 | 1.457B |
| June 15, 2026 | 1.464B |
| June 12, 2026 | 1.388B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bristol Myers Squibb Co. | 171.44B |
| Johnson & Johnson | 685.82B |
| Eli Lilly & Co. | 1.220T |
| Pfizer Inc. | 211.20B |
| EyePoint, Inc. | 255.76M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.84M |
| Revenue (Quarterly) | 31.69M |
| Total Expenses (Quarterly) | 94.53M |
| EPS Diluted (Quarterly) | -0.1802 |
| Gross Profit Margin (Quarterly) | 68.42% |
| Profit Margin (Quarterly) | -198.3% |
| Earnings Yield | -6.25% |
| Normalized Earnings Yield | -6.040 |